Secondary Logo

Share this article on:

A giant aggressive angiomyxoma of vulva in a young woman

A case report

Xie, Yao, MMa; Qian, Yanping, PhDb; Zou, Bingyu, MMa,*

Section Editor(s): NA.,

doi: 10.1097/MD.0000000000013860
Research Article: Clinical Case Report

Rationale: Aggressive angiomyxoma (AAM) is a rare and benign invasive mesenchymal stromal tumor predominantly in women at reproductive age. AAM tends to relapse locally and should be differentially diagnosed from other mesenchymal tumors.

Patient concerns: We report here a rare case of massive vulvar AAM in a 22-year-old Chinese woman with left labia majora mass with ulcer.

Diagnoses: The diagnosis “aggressive angiomyxoma of vulva” was based on clinicopathologic and immunohistochemical features.

Interventions: A surgery with local excision of the mass was performed.

Outcomes: The patient was discharged 12 days after the surgery. There was no AAM recurrence or metastasis in a period of 12-month follow-up.

Lessons: The vulvar AAM is a benign and aggressive mesenchymal tumor. In this case, we present the diagnosis, treatment, and prognosis for vulvar AAM. The tumor was removed completely by the surgery, but a long-term follow-up is requisite for surveilling on recurrence.

aDepartment of Gynecology and Obstetrics, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

bDepartment of Gynecology and Obstetrics, Key Laboratory of Obstetrics & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan, China.

Correspondence: Bingyu Zou, Department of Gynecology and Obstetrics, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, No 32, West Second Section First Ring Road, Chengdu 610072, China (e-mail: dr_zoubingyu@163.com).

Abbreviations: AAM = aggressive angiomyxoma, ER = estrogen receptor, HE = hematoxylin and eosin, Hsp = hot-shock protein, SMA = smooth muscle actin.

Written informed consent was obtained from the patient herself for publication of this case report and any anonymized accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

The authors have no funding and conflicts of interest to disclose.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0

Received July 29, 2018

Accepted December 5, 2018

Back to Top | Article Outline

1 Introduction

Aggressive angiomyxoma (AAM) was 1st described in 1983.[1] AAM occurs very rarely and is an aggressive mesenchymal tumor. AAM grows in a slow and insidious manner as well as possesses a moderate-to-high risk of local relapse without clinical symptoms. AAM has poor long-term prognosis. AAM could appear in vulva, perineal region, buttocks, or pelvis in women at reproductive age.[2,3] So far, the underlying causes for AAM remain unclear. A few of recent studies suggest that AAM may be associated with chromosome alteration in 12q13-15 region[4,5] and aberrant HMGIC (DNA architectural factor gene) expression induced by chromosomal translocation t(8;12).[6] Here, we report a case with a giant vulvar AAM and describe the treatment procedure for the patient, together with a literature review on AAM.

Back to Top | Article Outline

2 Case report

A 22-year-old female (gravida 0, para 0) was presented with a giant solid mass on the left vulva with pruritus for 4 years. The vulva mass was small (about 0.5 cm × 0.3 cm) with slight pruritus. No treatment was given because she did not pay attention to it at the beginning. The mass was growing and increasing in size slowly, without fever, redness, secreta, dysmenorrhea, burning sensation, bleeding, abdominal pain, perineum pain, dysuria, difficulty in defecation, or other symptoms. She did not visit the hospital because of self-consciousness until she found ulcers on its surface. She had no history of surgery, inflammatory disease, medications, or trauma and her family history was unremarkable. The mass was long, irregular shaped, well-circumscribed, pedunculated, soft, spongy in consistency, and nontender. The size of the mass was about 30 cm × 20 cm with a pedicle of 8 cm × 2 cm. The pedicle extended from the middle left vulva to perineal body with several ulcers on the surface (Fig. 1A). No enlarged inguinal lymph nodes were palpated bilaterally. Bimanual examination revealed that no nodules appeared on vaginal, cervix, uterus, or bilateral accessory. Surface body ultrasound showed that several vessels were observed in the perineum of the mass with a sign of rich blood flow signal. There was also a slight blood flow signal in its distal internal of the mass. No abnormality was found in the pelvic and abdominal cavity in enhanced magnetic resonance imaging, transvaginal ultrasound, or the examination of tumor biomarkers like carcinoembryonic antigen CA125 and CA199 or alpha-fetoprotein. Of note, hot-shock protein 90 (Hsp90) rose to 134.20 ng/mL out of a standard range of 0 to 82.06 ng/mL.

Figure 1

Figure 1

The patient underwent surgical excision of the mass. The histopathologic examination of the resected mass confirmed the diagnosis of AAM. Blood vessels with various sizes and thicken walls were found in hematoxylin and eosin (HE) staining. No hemorrhagic or necrotic areas were observed. The tumor was composed of small spindle and stellate fibroblasts and mitotic cells were absent (Fig. 2). The stromal tissues had bland cells immingled with myxoid background and thin-walled capillaries. In immunohistochemistry assay, the tumor cells were positive for estrogen receptor (ER), α-smooth muscle actin (SMA) and vascular marker CD34 but were negative for cytokeratin (CK), progesterone receptor (PR), S-100, β-catenin, myogenin, and desmin. The cell proliferation marker Ki67 accounted for about 2% of total cells (Fig. 3). The patient was discharged 12 days after a surgery with satisfactory outcomes. No evidence of recurrence or distant metastasis was observed during the 12-month follow-up period (Fig. 1B).

Figure 2

Figure 2

Figure 3

Figure 3

Back to Top | Article Outline

3 Discussion

The AAM mainly occurs on the vagina, vulva, pelvic cavity, perineum, hips, and crissum in reproductive female aging from 30 to 40 years old. Occasionally, AAM may occur in men. The morbidity rate of male versus female is about 1:6.[7,8] AAM is aggressive due to its nature of local infiltration and recurrence.[9] The rate of AAM relapse varies from 35% to 72%.[10]

The AAM diameter ranges from 2 to 60 cm with an average of 12.7 cm.[11] AAM may or may not have envelope and present in a spherical or leaf-like shape. AAM is either soft or hard, or possesses a finger-like protrusion to neighboring tissues in some cases. In HE staining, the tumor cells are spindle or star-shaped, among in the mucus interstitial background with unclear boundaries. A large number of blood vessels are disordered and scattered randomly in AAM. Blood vessels with a middle size have thickened walls and do not appear to be in an anastomosis. There is no reticular vascular formation. The diameter and thickness of vascular tube range from fine arteries to larger arteries. The eosinophilic spindle cells are often tightly or loosely bunched around blood vessels.[12]

The AAM predominantly occurs in the perineal and pelvic regions, which leads to a possible misdiagnosis as Bartholin gland cyst or hernia.[13] Moreover, AAM is also difficult to distinguish from angiomyofibroblastoma due to similar morphology.[14,15] Therefore, the diagnosis of AAM should be based on both clinical features and histologic pathologies.

The tumor maker CEA, CA125, or CA199 is normal in the complete blood count, which is consistent with the previous finding.[16] In this case, the Hsp90 level was elevated, consistent with the role of Hsp90 playing an essential role in cancer and being also correlated with poor prognosis in cancer.[17–19] To some extent, it seems that AAM possesses potentially malignant or a tendency of regrowth. At gene expression level, AAM has a positive expression of vimentin, SMA, MSA, desmin, CD34, F8, ER, PR,[20] and negative expression for S-100, CK, and CD68.[21,22] This suggests that AAM is characterized by differentiation into fibroblasts and muscle fibroblasts.

The surgical removal of the tumor is the main treatment for AAM. Drug therapy, such as GnRH agonists, possesses therapeutic effect such as shrinking AAM or retarding its recurrence as an adjunct therapy in some cases. Since ERs or PRs are commonly positive in AAM, targeting ERs or PRs may be used as a potential therapeutic target.[23–25] Other treatment method such as vascular embolism (ER and PR positive) may be used as adjuvant therapy, while radiotherapy and chemotherapy have an undefined and limited role. Given that its characteristics of aggression and relapse, appropriate management and long-term follow-up are necessary.

In conclusion, in this case, AAM is a locally benign and aggressive mesenchymal entity and the surgical removal of the solid mass cures the AMM without a sign of recurrence during 12-month follow-up. A long-term surveillance is further required for this treated patient with AAM.

Back to Top | Article Outline

Author contributions

Conceptualization: Yao Xie, Bingyu Zou.

Data curation: Yao Xie, Yanping Qian, Bingyu Zou.

Formal analysis: Yao Xie, Yanping Qian.

Funding acquisition: Bingyu Zou.

Investigation: Yao Xie, Yanping Qian.

Methodology: Yao Xie, Yanping Qian.

Project administration: Yao Xie, Bingyu Zou.

Resources: Yao Xie, Yanping Qian, Bingyu Zou.

Supervision: Bingyu Zou.

Writing – original draft: Yao Xie, Yanping Qian.

Writing – review & editing: Bingyu Zou.

Back to Top | Article Outline

References

[1]. Steeper TA, Rosai J. Aggressive angiomyxoma of the female pelvis and perineum. Report of nine cases of a distinctive type of gynecologic soft-tissue neoplasm. Am J Surg Pathol 1983;7:463–75.
[2]. Mccluggage WG, Connolly L, Mcbride HA. HMGA2 is a sensitive but not specific immunohistochemical marker of vulvovaginal aggressive angiomyxoma. Am J Surg Pathol 2010;34:1037–42.
[3]. Giraudmaillet T, Mokrane FZ, Delchier-Bellec MC, et al. Aggressive angiomyxoma of the pelvis with inferior vena cava involvement: MR imaging features. Diagn Interv Imaging 2015;96:111–4.
[4]. Elkattah R, Sarkodie O, Otteno H, et al. Aggressive angiomyxoma of the vulva: a precis for primary care providers. Case Rep Obstet Gynecol 2013;2013:183725.
[5]. Srinivasan R, Mohapatra N, Malhotra S, et al. Aggressive angiomyxoma presenting as a vulval polyp. Indian J Cancer 2007;44:87–9.
[6]. Nucci MR, Weremowicz S, Neskey DM, et al. Chromosomal translocation t(8;12) induces aberrant HMGIC expression in aggressive angiomyxoma of the vulva. Genes Chromosomes Cancer 2001;32:172–6.
[7]. Han-Geurts IJ, van Geel AN, van Doorn L, et al. Aggressive angiomyxoma: multimodality treatments can avoid mutilating surgery. Eur J Surg Oncol 2006;32:1217–21.
[8]. Small W Jr, Bacon MA, Bajaj A, et al. Cervical cancer: a global health crisis. Cancer 2017;123:2404–12.
[9]. Sereda D, Sauthier P, Hadjeres R, et al. Aggressive angiomyxoma of the vulva: a case report and review of the literature. J Low Genit Tract Dis 2009;13:46–50.
[10]. Mathieson A, Chandrakanth S, Yousef G, et al. Aggressive angiomyxoma of the pelvis: a case report. Can J Surg 2007;50:228–9.
[11]. Jingping Z, Chunfu Z. Clinical experiences on aggressive angiomyxoma in China (report of 93 cases). Int J Gynecol Cancer 2010;20:303–7.
[12]. McCluggage WG. Recent developments in vulvovaginal pathology. Histopathology 2009;54:156–73.
[13]. Sutton BJ, Laudadio J. Aggressive angiomyxoma. Arch Pathol Lab Med 2012;136:217–21.
[14]. Fletcher CD, Tsang WY, Fisher C, et al. Angiomyofibroblastoma of the vulva. A benign neoplasm distinct from aggressive angiomyxoma. Am J Surg Pathol 1992;16:373–82.
[15]. Nucci MR, Fletcher CD. Vulvovaginal soft tissue tumours: update and review. Histopathology 2000;36:97–108.
[16]. Shoji T, Takeshita R, Mukaida R, et al. Angiomyofibroblastoma of the vulva diagnosed preoperatively: a case report. Mol Clin Oncol 2017;7:407–11.
[17]. Boroumand N, Saghi H, Avan A, et al. Therapeutic potency of heat-shock protein-90 pharmacological inhibitors in the treatment of gastrointestinal cancer, current status and perspectives. J Pharm Pharmacol 2018;70:151–8.
[18]. Miyata Y, Nakamoto H, Neckers L. The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des 2013;19:347–65.
[19]. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002;2:3–24.
[20]. Smith HO, Worrell RV, Smith AY, et al. Aggressive angiomyxoma of the female pelvis and perineum: review of the literature. Gynecol Oncol 1991;42:79–85.
[21]. Dahiya K, Jain S, Duhan N, et al. Aggressive angiomyxoma of vulva and vagina: a series of three cases and review of literature. Arch Gynecol Obstet 2011;283:1145–8.
[22]. Dierickx I, Deraedt K, Poppe W, et al. Aggressive angiomyxoma of the vulva: a case report and review of literature. Arch Gynecol Obstet 2008;277:483–7.
[23]. Haldar K, Martinek IE, Kehoe S. Aggressive angiomyxoma: a case series and literature review. Eur J Surg Oncol 2010;36:335–9.
[24]. McCluggage WG, Jamieson T, Dobbs SP, et al. Aggressive angiomyxoma of the vulva: dramatic response to gonadotropin-releasing hormone agonist therapy. Gynecol Oncol 2006;100:623–5.
[25]. Poirier M, Fraser R, Meterissian S. Case 1. Aggressive angiomyxoma of the pelvis: response to luteinizing hormone-releasing hormone agonist. J Clin Oncol 2003;21:3535–6.
Keywords:

aggressive angiomyxoma; vulva; mesenchymal tumor

Copyright © 2019 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.